Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that Shionogi and Osaka University (Location: Suita, Osaka, President: Shojiro Nishio) have established a joint research laboratory (research lab’s name: Joint Research Laboratory…
AbbVie (NYSE: ABBV) announces today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the supplemental Biologics License Application (sBLA) concerning epcoritamab-bysp, a subcutaneously administered T-cell engaging bispecific antibody. This treatment targets adult patients with relapsed…
Bristol Myers Squibb (NYSE: BMY) has confirmed the conclusion of its tender offer, initially announced, to acquire all outstanding shares of RayzeBio, Inc. (Nasdaq: RYZB) common stock at a price of $62.50 per share in cash, totaling approximately $4.1 billion.…
The U.S. Food and Drug Administration (FDA) has given priority review status to the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab), marking its sixth potential indication. This review targets its use as an add-on maintenance treatment for specific adult…
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval…
Today, Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has officially launched the application process for its 2024 BOTOX® Cosmetic grant program, aimed at supporting women entrepreneurs. Following a successful partnership with IFundWomen in 2023, this year marks the second…
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company dedicated to enhancing the well-being of individuals with severe autoimmune conditions, has announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA)…
Leading global pharmaceutical company Lupin Limited (Lupin) has announced the introduction of Ganirelix Acetate Injection, 250 mcg mL, Single-Dose Prefilled Syringe, following approval from the United States Food and Drug Administration (U.S. FDA). This generic equivalent to the reference listed…
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) revealed today that it has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for its experimental drug olezarsen. This designation is specifically for the treatment of familial chylomicronemia syndrome (FCS), a…
Today marks the completion of GSK’s acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company dedicated to addressing the unmet medical needs of patients with respiratory and inflammatory conditions. As previously disclosed, this acquisition encompasses AIO-001, a promising long-acting anti-thymic…
Zoetis, a global leader in animal health, has announced its financial results for the fourth quarter and full year 2023, along with full-year guidance for 2024. In the fourth quarter of 2023, Zoetis reported revenue of $2.2 billion, marking an…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy. CASGEVY is now approved for treating patients aged 12 and older with severe sickle cell…